AG
RARX

Advisor Group’s Ra Pharmaceuticals, Inc. Common Stock RARX Stock Holding History

Advisor Group’s Portfolio RARX Stock Details RARX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$9K Sell
184
-13
-7% -$575 ﹤0.01% 4441
2019
Q3 		$5K Buy
197
+103
+110% +$3.05K ﹤0.01% 4708
2019
Q2 		$2K Buy
94
+81
+623% +$1.85K ﹤0.01% 5040
2019
Q1 		$0 Buy
+13
New +$279 ﹤0.01% 5416

Other funds holding RARX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.6B AUM 93.19% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Advisor Group's RARX Position: Q4 2019 in Review

Advisor Group reduced its Ra Pharmaceuticals, Inc. Common Stock (RARX) stake by 6.6% in Q4 2019, selling an estimated $575 and leaving 184 shares worth $9K. The position accounts for ﹤0.01% of the portfolio, ranked #4441.

Advisor Group first reported a position in RARX in Q1 2019 and has held it in 4 quarters since. 146 funds tracked by Wall St. Rank hold RARX as of Q4 2019.

  • Advisor Group held 184 shares of Ra Pharmaceuticals, Inc. Common Stock worth $9K as of Q4 2019.
  • Advisor Group sold 13 Ra Pharmaceuticals, Inc. Common Stock shares in Q4 2019, an estimated $575.
  • Ra Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #4441 holding.
  • Advisor Group first reported a position in Ra Pharmaceuticals, Inc. Common Stock in Q1 2019 and has held it in 4 quarters since.
  • 146 funds tracked by Wall St. Rank held Ra Pharmaceuticals, Inc. Common Stock as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.